Syngene International
Indian contract research and manufacturing org serving global pharma discovery to manufacturing.
On the record
Checkpoint: Q1 FY27 earnings, first results under new CEO Siddharth Mittal
The call
A profitable, contract-locked CRDMO absorbing a client destocking hit while a new CEO takes over and rivals stay mostly boxed out by US rules.
Syngene is a company that manufactures drugs and runs experiments for large pharmaceutical companies like Bristol Myers Squibb. It is hard to replace because it has FDA-approved factories, long-term contracts with major clients locked in until 2035, and switching to a new manufacturer is expensive and time-consuming for drug companies. However, one customer's decision to reduce orders (Zoetis, which buys Librela) just cut profits by 20 percent, showing that Syngene depends too heavily on a few big buyers. The company also is getting a new CEO in mid-2026, and profit margins are expected to shrink in the first half of 2027. The next earnings report in late July or August 2026 will tell investors whether losing that one customer's orders is just a temporary bump or a sign that more customers might pull back.
Why
01
AI pressure: AI-native drug discovery firms (Exscientia, BenevolentAI, Recursion). AI discovery tools chip at early-stage research fees, but Syngene's manufacturing and GMP work stays largely untouched. Could AI do the core job? Unlikely.
02
Bigger players: WuXi AppTec. WuXi still competes for pharma clients worldwide even as a Pentagon designation blocks it in the US market through 2028. Could a giant copy it? Probably.
03
What protects it. FDA-inspected plants, contracts like the BMS deal running to 2035, and switching costs baked into regulatory approvals lock clients in for years.
What would change this call
Syngene's Q1 FY27 earnings print (expected late July/August 2026) under new CEO Siddharth Mittal. Shows whether margin bleed and client softness continue or stabilize.
Any second large client reducing orders before FY28. Would indicate Librela was not an isolated event but a pattern of client concentration risk.
Outcome of WuXi AppTec's federal litigation against its Pentagon designation. Determines whether China+1 order shifts toward Syngene persist or reverse.
Any second large client reducing orders before FY28. Would indicate Librela was not an isolated event but a pattern of client concentration risk.
Outcome of WuXi AppTec's federal litigation against its Pentagon designation. Determines whether China+1 order shifts toward Syngene persist or reverse.
Key numbers
- FY26 revenue Rs3,738.7 crore, up 3% YoY
- FY26 profit fell 20% to Rs316.7 crore
- FY26 EBITDA margin ~25%, down from 29% in FY25
Named risks
- Client concentration: single Zoetis Librela destocking event cut FY26 profit by 20%.
- New CEO transition (July 1, 2026) creates execution uncertainty during a margin trough.
- Guidance signals almost no Librela revenue in Q1 and Q2 FY27, delaying growth recovery to FY28.
- US Section 232 pharmaceutical tariffs (100% on patented drugs and APIs) effective July 31, 2026 for large firms could raise trade tension despite current exemptions for biosimilars and animal health.
- WuXi AppTec contesting Pentagon designation in federal court, and a 2028 grandfather period, could limit near-term contract wins for Syngene.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| WuXi AppTec | gaining on | WuXi hit with Pentagon Chinese military company designation June 8, 2026, opening opportunity for Syngene to capture displaced China+1 business |
| Piramal Pharma Solutions | contesting | Both named among Goldman Sachs preferred CRDMO Buy picks ahead of Q1 FY27 earnings, July 8, 2026 |
| Divi's Laboratories | contesting | Competing Indian CRDMO peer also flagged by Goldman Sachs as a China+1 beneficiary, July 2026 |
| Anthem Biosciences | gaining on | Cited as an Indian CDMO peer outpacing sector rivals in industry comparison analysis, July 2025 |
| Exscientia, BenevolentAI, Recursion (AI-native drug discovery firms) | contesting | AI-native firms push molecules faster through early discovery but have suffered clinical setbacks, per April 2025 industry review |
Questions people ask
- Is Syngene International profitable in 2026?
- Yes, but profit fell. Syngene's FY26 (year ended March 31, 2026) profit after tax was Rs 316.7 crore, down 20% from Rs 496.2 crore in FY25, mainly due to reduced orders from a large biologics client tied to Zoetis's Librela, per Business Today, April 29, 2026.
- Who owns Syngene International?
- Syngene is majority owned by Biocon Limited, which held roughly 52.68% of shares as of FY26, with the rest split between foreign institutional investors (about 13.9%) and domestic mutual funds and institutions (about 26.4%), per The Hindu BusinessLine, July 9, 2026.
- Could AI replace Syngene International's services?
- Not wholesale. AI tools can accelerate early discovery steps like hit optimization and ADMET prediction, but no fully AI-designed drug is on the market yet, and Syngene's GMP manufacturing plants, FDA inspection history, and long-term contracts like the BMS deal extended to 2035 remain outside AI's reach, per an April 2025 drug discovery industry review.
- Who is Syngene International's biggest competitor?
- Domestically, Syngene competes with Piramal Pharma Solutions, Divi's Laboratories, Anthem Biosciences, Sai Life Sciences, and Cohance Lifesciences; globally, WuXi AppTec was the largest CRDMO until the US Pentagon designated it a Chinese military company on June 8, 2026, potentially shifting contracts to Indian peers.
- Did Syngene International have layoffs in 2026?
- Syngene's FY26 annual report disclosed exceptional charges tied to employee termination benefits, suggesting some restructuring occurred during the year, though no specific headcount reduction figure was reported, per Economic Times, April 30, 2026.
- What caused Syngene International's FY26 profit drop?
- Syngene's FY26 profit after tax fell 20% to Rs 316.7 crore, which management attributed to destocking and reduced orders from a single large biologics manufacturing client, widely reported as related to Zoetis's Librela product, per Business Today, April 29, 2026.
Timeline
- 2026-07-09The Hindu BusinessLine reports FY26 revenue rose 3% while profit fell 20%
- 2026-07-01Siddharth Mittal, former Biocon CEO, becomes Syngene's new MD and CEO
- 2026-06-08US Pentagon designates WuXi AppTec a Chinese military company
- 2026-04-30Q4 FY26 results show revenue of Rs 1,037 crore, net profit down 19% YoY
- 2026-04-29Business Today reports FY26 PAT fell 20% to Rs 316.7 crore on biologics client impact
- 2025-07-23Q1 FY26 results show revenue up 11% YoY to Rs 875 crore, net profit up 59%
- 2025-03-30FY25 annual report discloses workforce of 8,235 employees including 5,641 scientists
- 2025-03-10Syngene acquires first US manufacturing facility in Baltimore from Emergent BioSolutions for $36.5 million
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Syngene International Limited (NSE: SYNGENE) (2026-03-09)
- Syngene's FY26 profit falls 20% as biologics client impact weighs on margins (2026-04-29)
- Syngene FY26 profit falls 20%, revenue rises 3% (2026-07-09)
- gurufocus.com (2026-07-26)
- Syngene Reports 59% Surge in Net Profit and ₹875 Crore Revenue in Q1 FY26 (2025-07-23)
- Syngene shares zoom 17% even as firm's Q4 net profit drops 19% YoY (2026-04-30)
- Directors Report of Syngene International Ltd. Company
- India's CDMO Moment (2026-06-09)
- Syngene International Ltd Directors Report
- Advancing Science, Enabling Innovation (2025-03-30)
- Syngene International Number of Employees 2026 (2026-06-29)
- Syngene Acquires its First Manufacturing Facility in the US (2025-03-10)